JP2016128507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128507A5 JP2016128507A5 JP2016058155A JP2016058155A JP2016128507A5 JP 2016128507 A5 JP2016128507 A5 JP 2016128507A5 JP 2016058155 A JP2016058155 A JP 2016058155A JP 2016058155 A JP2016058155 A JP 2016058155A JP 2016128507 A5 JP2016128507 A5 JP 2016128507A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- virus
- leukemia
- crystal
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000013078 crystal Substances 0.000 claims 12
- 102000014150 Interferons Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 241000709661 Enterovirus Species 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 claims 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 241000709664 Picornaviridae Species 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000008601 Polycythemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 241000315672 SARS coronavirus Species 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 230000003187 abdominal effect Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000024207 chronic leukemia Diseases 0.000 claims 2
- 239000011549 crystallization solution Substances 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000005252 hepatitis A Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 208000020352 skin basal cell carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009510 drug design Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910259339.2 | 2009-12-18 | ||
| CN2009102593392A CN102101886A (zh) | 2009-12-18 | 2009-12-18 | 构象改变的重组干扰素晶体、其三维结构及应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543445A Division JP2013514279A (ja) | 2009-12-18 | 2010-12-16 | 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016128507A JP2016128507A (ja) | 2016-07-14 |
| JP2016128507A5 true JP2016128507A5 (enrdf_load_stackoverflow) | 2016-08-25 |
Family
ID=44154975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543445A Pending JP2013514279A (ja) | 2009-12-18 | 2010-12-16 | 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用 |
| JP2016058155A Pending JP2016128507A (ja) | 2009-12-18 | 2016-03-23 | 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543445A Pending JP2013514279A (ja) | 2009-12-18 | 2010-12-16 | 変更された空間構成を有する結晶性組換型インターフェロン、その三次元構造、およびその使用 |
Country Status (11)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102101886A (zh) | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
| TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| US9830422B1 (en) * | 2013-07-22 | 2017-11-28 | The Curators Of The University Of Missouri | In silico biological and pharmaceutical modeling |
| WO2015103643A2 (en) | 2014-01-06 | 2015-07-09 | The General Hospital Corporation | Integrin antagonists |
| MY194322A (en) * | 2015-05-12 | 2022-11-28 | Superlab Far East Ltd | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
| WO2019134318A1 (zh) * | 2018-05-09 | 2019-07-11 | 深圳晶泰科技有限公司 | 药物晶体结构全景分析系统及其全景分析方法 |
| CN111508568B (zh) * | 2020-04-20 | 2023-08-29 | 腾讯科技（深圳）有限公司 | 分子生成方法、装置及计算机可读存储介质和终端设备 |
| CN111658779A (zh) * | 2020-06-22 | 2020-09-15 | 四川大学华西医院 | 治疗新型冠状病毒肺炎的联合用药物 |
| CN113223631B (zh) * | 2021-05-06 | 2024-05-24 | 吉林大学 | 一种晶体结构解析方法及系统 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4672108A (en) | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
| WO1999045389A2 (en) | 1998-03-06 | 1999-09-10 | Abbott Lab | Ligand screening and design by x-ray crystallography |
| CN1062565C (zh) | 1998-06-29 | 2001-02-28 | 深圳九先生物工程有限公司 | 重组人α型复合干扰素及其制备方法和用途 |
| US6833256B1 (en) * | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
| US7666995B2 (en) | 2000-11-03 | 2010-02-23 | Pestka Biomedical Laboratories | Interferons, uses and compositions related thereto |
| WO2002044197A2 (en) * | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
| CN1245215C (zh) * | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| US20060035327A1 (en) | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
| FR2823764B1 (fr) * | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
| AU2004269390A1 (en) | 2003-08-28 | 2005-03-10 | Huiyangtech (Usa), Inc. | Uses of spatial configuration to modulate protein function |
| US7585647B2 (en) * | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| CN1910195A (zh) * | 2003-08-28 | 2007-02-07 | 辉阳科技美国公司 | 通过空间构象调节蛋白质功能 |
| PT2325202E (pt) | 2003-08-28 | 2015-02-05 | Superlab Far East Ltd | Utilizações de interferões com estrutura espacial alterada |
| WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
| CN1740197B (zh) * | 2004-08-26 | 2010-05-12 | 辉阳科技美国公司 | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 |
| JP2006083126A (ja) * | 2004-09-17 | 2006-03-30 | Institute Of Physical & Chemical Research | タンパク質の結晶化試薬キット及び試薬キットを利用した結晶化スクリーニング方法 |
| EP2537527A3 (en) | 2005-03-09 | 2013-02-20 | Guangwen Wei | Uses of recombinant super-compound interferons |
| CN1710197B (zh) * | 2005-06-17 | 2011-06-22 | 徐州师范大学 | 可变色彩色纤维防伪纸 |
| JP4744979B2 (ja) * | 2005-08-24 | 2011-08-10 | 独立行政法人理化学研究所 | ゼオライトを用いたタンパク質結晶化方法 |
| JP2008050225A (ja) * | 2006-08-25 | 2008-03-06 | National Institute Of Advanced Industrial & Technology | たんぱく質の合理的な結晶化条件探索法 |
| CN102101886A (zh) | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
| US20130184437A9 (en) | 2011-06-08 | 2013-07-18 | Guangwen Wei | Design and use of new recombinant interferons with altered spatial configuration and three-dimensional structure |
-
2009
- 2009-12-18 CN CN2009102593392A patent/CN102101886A/zh active Pending
-
2010
- 2010-12-16 JP JP2012543445A patent/JP2013514279A/ja active Pending
- 2010-12-16 WO PCT/CN2010/002055 patent/WO2011072487A1/zh active Application Filing
- 2010-12-16 CN CN201080057897.1A patent/CN102770447B/zh active Active
- 2010-12-16 KR KR1020127017945A patent/KR20120108985A/ko not_active Ceased
- 2010-12-16 ES ES10836926.5T patent/ES2631028T3/es active Active
- 2010-12-16 US US13/516,947 patent/US8846025B2/en active Active
- 2010-12-16 MY MYPI2012002756A patent/MY169650A/en unknown
- 2010-12-16 CA CA2784624A patent/CA2784624C/en active Active
- 2010-12-16 EP EP10836926.5A patent/EP2514761B1/en active Active
- 2010-12-16 SG SG2012044889A patent/SG181785A1/en unknown
- 2010-12-16 AU AU2010333574A patent/AU2010333574B2/en active Active
- 2010-12-17 US US12/971,956 patent/US8415151B2/en active Active
-
2014
- 2014-08-15 US US14/461,360 patent/US9273109B2/en active Active
-
2016
- 2016-03-23 JP JP2016058155A patent/JP2016128507A/ja active Pending